Introduction {#s1}
============

Dexmedetomidine (DEX), a pharmacological alpha 2-adrenergic agonist, which induces sympatholytic mechanism on the brain with anxiolytic and sedative effects ([@B29]). DEX triggers the sedative pathways, causing a type of mild sedation and minimizing the risk of respiratory depression. This drug is mainly used in two settings: (1) in intensive care for moderate sedation, although it is not recommended for long-term sedation; and (2) in anesthesia as a stand-alone sedative or as co-adjuvant for general anesthesia. In both settings, DEX has shown interesting cardiovascular, respiratory, anti-inflammatory, and organ protective properties. In clinic, it is used in perioperative sedation and intensive care, due to its analgesic and anxiolytics effects. The drug is commonly administered intravenously, either as a single bolus of approximately 1 μg/kg or as a bolus plus a continuous infusion ranging between 0.2 and 1 μg/kg/h. The stimulus of the different subtypes of α2-adrenergic receptors (α2A, α2B, α2C) and its location in the nervous system (pre or postsynaptic), will determine the different effects observed during use. Currently, many biological functions of DEX have been demonstrated in different animal models, through several signaling pathways.

Currently, the biological functions of DEX have been demonstrated in different animal models through several signaling pathways. Some studies demonstrate the beneficial effects of DEX against ischemia--reperfusi0on (I/R) injury ([@B148]; [@B38]), activating the eNOS/NO cardioprotective signaling pathways. *In vivo* mechanistic studies are needed to determine the effects of DEX in clinical events that are associated with I/R. This review shows that DEX may be a pharmacological agent that modulates the organ I/R injury responses in humans.

Pharmacokinetic Properties {#s2}
==========================

DEX is an imidazole derivative with a 236.7 g/mol molecular mass and a 2.89 octanol/water partition coefficient ([@B145]). Loading doses and infusion rates are determined on a milligram per kilogram total body weight (TBW). In general, linear pharmacokinetics adequately describes the body disposition of the drug, even after prolonged high dose administration in critically ill patients ([@B77]; [@B180]). However, patients with severe hepatic failure or obstructive jaundice have shown a reduction of metabolic clearance (CL) and significant changes in the volume of distribution (VD) ([@B31]; [@B166]). DEX CL remains stable with dose increments within the therapeutic range and decreases with the administration of supratherapeutic doses ([@B44]; [@B79]).

Even though DEX was developed for intravenous use, it has been administered by different routes with variable bioavailability. Intramuscular administration has shown bioavailability of 103.6% with a time to peak of 1.7 ± 1.8 h ([@B5]). Nasal or buccal (submucosal) administration has been successfully used in patients without available venous access, avoiding high plasma peak levels. The bioavailability and time to peak of the nasal approach is 65% (35--93%) and 38 (15--60) min, respectively ([@B78]; [@B198]). The bioavailability and time to peak of the buccal route is 81.8% (72.6--92.1%) and 1.5 ± 0.2 h, respectively. Due to an extensive first-pass effect, the bioavailability of the drug reaches only 15.6% after oral administration ([@B5]). DEX has a high protein binding (94%) with an extensive VD and easily crosses the blood-brain barrier ([@B15]). In non-compartmental kinetics, the administration of a single bolus has a 6.5 ± 3.4 min distribution half-life ([@B5]). The drug has a described steady state VD of 80--194 l, which is related to patient weight ([@B45]; [@B96]; [@B180]). ICU patients tend to have greater variability of this parameter (109--223 l), and hypoalbuminemia has been shown to increase the VD in these patients ([@B79]; [@B68]).

The drug is extensively metabolized in the liver with a determined extraction ratio of 0.7, and less than 1% of the drug eliminated without changes ([@B5]). DEX undergoes N-glucuronidation (34%) by uridine diphosphate glucuronosyltransferases (UGT2B10, UGT1A4) and is also hydroxylated in a smaller proportion by the P450 enzyme system, specifically CYP2A6 ([@B1]; [@B85]; [@B99]). The generated metabolites are approximately 100 times less potent than the original administered drug and are considered inactive. These metabolites are finally eliminated *via* the kidneys (95%). The CL is 36--42 l/h in average adult patients ([@B45]; [@B96]). In ICU patients, CL has been defined at 31.8--57 l/h ([@B183]; [@B201]). In healthy volunteers, the elimination half-life is 2.1--3.1 h, and in ICU patients, the half-life slightly increases to 2.2--3.7 h ([@B90]; [@B183]; [@B201]). In this context, the presence of hypoalbuminemia decreases or increases half-life times ([@B77]; [@B201]). However, as a drug with a high hepatic extraction ratio, DEX CL would depend more on the blood flow to the liver (cardiac output) than on protein binding ([@B13]). It has been reported that a 19% cardiac output reduction decreases DEX CL by 12% ([@B44]).

Numerous factors influencing the DEX dosage have been reported in the literature. Conditions such as hypoalbuminemia, liver dysfunction, reduced cardiac output, and hemodynamic alterations significantly affect both the VD and CL ([@B90]; [@B44]; [@B201]). Several pharmacokinetic models developed in different populations show that observed inter-individual variability of DEX body disposition is explained by the influence of the aforementioned covariates on pharmacokinetic parameters and patient dose requirements. Other covariates, such as ethnicity and polymorphisms of metabolic enzymes, are less relevant contributors to the described variability ([@B91]; [@B90]; [@B103]; [@B99]).

In adults, the majority of these experimental models were derived from four trials of critically ill patients or healthy volunteers in which different DEX continuous infusions with varying durations were used. In most studies, a 2-compartment model adequately describes the disposition and elimination of DEX ([@B96]; [@B183]; [@B201]; [@B30]). Fewer trials have described models of 1 and 3 compartments ([@B45]; [@B44]; [@B109]; [@B64]). In these models, the VD has been correlated with patient age, TBW, free-fat mass (FFM), albuminemia, and the intercurrence of surgery. The CL varies according to patient height, TBW, FFM, albuminemia, and alanine aminotransferase metabolic activity. The review article by Weerink et al. evaluated the impact of different covariates on the DEX plasma concentration-time profile by means of comprehensive simulations ([@B187]). For this purpose, a DEX 35 µg loading dose infused over 10 min, followed by a 35 µg/h maintenance dose was simulated supporting the different published pharmacokinetic simulations. In a 2h DEX simulated infusion the authors found: 1) DEX reached concentrations after a bolus dose was directly dependent on patient albuminemia and inversely related to patient height, with a less significant influence of age on the observed maximum concentration; 2) the accomplished concentration during DEX infusion (steady state) was influenced by patient age, albuminemia, height, and body weight. These findings are in agreement with previously published data where age-associated metabolic CL reduction increases DEX plasma concentration in patients ([@B79]). Albuminemia and height may also influence DEX concentrations, but their impact is less clear compared to other more relevant covariates ([@B109]; [@B104]; [@B201]). For instance, available evidence suggests that DEX CL is significantly influenced by hepatic blood flow and cardiac output, but since DEX likely has a high hepatic extraction ratio, this influence is difficult to establish in all populations. However, the non-linear behavior of DEX CL has been described in non-compartmental and compartmental analyses where DEX concentration increments reduce the drug CL by reducing cardiac output ([@B44]; [@B79]). At present, changes in TBW or FFM have a significant impact on concentrations after a bolus and during the infusion of DEX and should be considered when dosing adult patients ([@B30]; [@B64]; [@B101]).

As previously mentioned, TBW emerges as a significant covariate that influences the concentrations of DEX. Infusion schemes using mass units of drug per kilogram of TBW do not seem appropriate for the obese individual, as they result in increased plasma levels than those observed in lean subjects. In a pharmacokinetic modeling analysis by Cortinez et al., lean tissues showed as fat-free mass (FFM) accounted for size-dependent changes in VD of DEX ([@B30]). In addition, they also showed that for any lean body mass, total CL decreased associated with major fat mass. In a second trial by the same study group, authors confirmed that lean body mass was an appropriate dosing scalar for size in obese patients and showed that decreased hepatic blood had a signiﬁcant effect on the CL of DEX ([@B152]). The observed CL reduction in this population is most probably explained by a relative overdose of obese patients caused by TBW-based dosing schemes. In this setting, scaling doses to FFM or allometric TBW seems more relevant ([@B30]; [@B64]; [@B152]).

Although the drug is not approved for clinical administration in the pediatric population, its off-label use is widely extended in these patients ([@B116]). DEX pharmacokinetics in children has been studied in ICU patients and in patients undergoing cardiac and non-cardiac surgery ([@B140]; [@B168]; [@B189]; [@B169]; [@B112]). A 2-compartment model, using TBW scaled to 1 for the VD and 0.75 for the CL (Equation 1), adequately describes the disposition of the drug in pediatric populations.
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where y is the variable of interest (e.g., Cl or V), a is the allometric coefficient, and PWR is the allometric exponent.

In children, 93% of DEX is protein bound with a rapid redistribution half-life of approximately 7 min and elimination half-life of 2 h ([@B137]; [@B118]). Weight appears as a significant covariate influencing DEX CL in children older than 2 years with nearby levels (within 30--40%) to those reported in adults ([@B137]). Several studies report the influence of the maturation of neonatal enzymatic activity on CL, but the available data are very dissimilar. At birth, a full-term neonate has a DEX CL of 43--54% adult values, and in a variable period (1 month--1 year) reaches adult values ([@B140]; [@B189]). Overall, allometric scaling can be used to predict DEX concentrations in children older than 1 year of age. In children younger than 1 year, inter-individual variability significantly influences the CL and is substantially greater than the impact of maturation on this parameter. Thus, despite considering maturation and patient age, it is difficult to achieve a certain predicted concentration in very small children.

Pharmacodynamic Properties {#s3}
==========================

In terms of the pharmacodynamic properties of DEX, it shows a high affinity and selectivity for the α2-adrenoceptors, this pharmacological characteristic determines a typical biphasic hemodynamic response. After infusion, DEX induces sympatholytic effect, such as a lower mean arterial blood pressure (MAP) and heart rate (HR) through activation of presynaptic α2-adrenoceptors in the central nervous system. In addition, DEX induces vasodilation through activation of α2-adrenoceptors in endothelial cells ([@B49]; [@B175]). At higher concentrations, vasoconstrictive effects of DEX are attributable to activation of α2-adrenoceptors in vascular smooth muscle, resulting clinically in an increase in MAP and diminution of HR ([@B165]). The pharmacokinetic and pharmacodynamic effects of DEX have been extensively studied in animal models, however its role in critical patients' arterial pressure and heart rate has been scarcely addressed ([@B46]; [@B165]; [@B141]).

Adverse Effects {#s3_1}
---------------

Adverse effects of dexmedetomidine are mainly restricted to hemodynamic alterations. These include hypertension, bradycardia, and hypotension owing to pre- and postsynaptic α2-receptor activation, which causes vasoconstriction, vasodilatation, and reflex bradycardia ([@B46]). Long-term use of dexmedetomidine leads to super sensitization and upregulation of receptors. With abrupt discontinuation, a withdrawal syndrome of nervousness, agitation, headaches, and hypertensive crisis can occur.

Common adverse effects for organ systems (1 to 10%) are: respiratory, Atelectasis, hypoxia, pulmonary edema, pleural effusion, respiratory failure, acute respiratory distress syndrome, bradypnea, pneumonia, pharyngolaryngeal pain, gastrointestinal, dry mouth, vomiting, constipation, abdominal distension, abdominal pain, diarrhea, hematologic, anemia, metabolic, hyperglycemia, hypoglycemia, hypocalcemia, acidosis, hypokalemia, hypomagnesemia, hypernatremia, hypophosphatemia, acute renal failure, and oliguria ([@B24]).

Dexmedetomidine is not recommended in patients with advanced heart block and ventricular dysfunction. FDA has classified it as a category C pregnancy risk, therefore the drug should be used with extreme caution in women who are pregnant ([@B123]).

Two major limitations regarding dexmedetomidine use, are its long-lasting effects and its hemodynamic side effects. A safe and quick reversal of these effects would benefit clinical practice, presumably leading to more widespread use of dexmedetomidine. The selective α2-antagonist atipamezole can effectively reverse dexmedetomidine's hemodynamic and sedative effects ([@B88]). The reduction in heart rate and blood pressure caused by dexmedetomidine is quickly reversed after IV administration of 15--150 µg/kg atipamezole. Higher doses of atipamezole (150 µg/kg) also reverse sedation. Transient orthosympathic activation, with a 10-fold increase in plasma norepinephrine levels, is seen with higher doses or fast infusion rates ([@B155]).

Effects on Cardiovascular and Ventilatory Physiology {#s3_2}
----------------------------------------------------

The US Food and Drug Administration (FDA) originally approved DEX for use in "initially intubated, mechanically ventilated patients," that is, in ventilated patients requiring sedation throughout and after extubation. Then [@B63] approved its use for the sedation of non-invasive intubated critical patients ([@B134]; [@B95]). Since DEX's appearance on the market as a sedative drug, cardiovascular and ventilatory effects have been extensively characterized ([@B39]).

The effects of DEX on the cardiovascular system are a consequence of the pharmacological modulation of the α-2 adrenergic receptor. The stimulation of the different subtypes of α2 adrenergic receptors (α2A, α2B α2C) and their location in the nervous system (pre or postsynaptic), will determine the different cardiovascular effects observed during its use. An intravenous bolus of DEX in healthy individuals determines a biphasic blood pressure response. DEX infusion induces an initial transient increase vasoconstriction in vascular smooth musculature (by activation of postsynaptic α2B receptors), followed by a decrease in blood pressure and heart rate (by the activation of α2A receptors in the central nervous system). This apparent dual action of the drug becomes evident when its effect is considered in sympathetically denervated territories, such as when an anesthetic blockade of peripheral nerve exists ([@B175]) or when high doses of the drug are used. In these situations, the peripheral vasoconstrictor effect of the drug predominates. The opposite effect, vasodilation associated with central sympatholysis is observed when low doses are used in subjects with a non-intervened sympathetic system. The omission of the DEX loading bolus prevents initial hypertension and reflex bradycardia ([@B76]). In addition, stimulation of postsynaptic α2-adrenergic receptors in endothelial cells would also induce vasodilation. In this context, the correct infusion rate of the drug, appropriate volume administration and clinical indication, make DEX a substance with a wide security therapeutic range ([@B86]). The central inhibition of the sympathetic system could minimize patient stress and instability in blood pressure during and after cardiac surgery ([@B58]). Evidence suggests that induced autonomic nervous system modulation during perioperative administration of DEX is associated with a trend towards improved cardiac outcomes following noncardiac surgery ([@B16]; [@B191]). In addition, this central inhibition of sympathetic discharge could prevent the sympathetic reservoir from being depleted, and therefore the Dex group has higher blood pressure compared to the control group. Mukhtar et al. used a dosage of 0.5 μg/kg/h by infusion, which was effective in diminishing the hemodynamic response to surgery without deleterious vasodepressor effects ([@B124]).

Despite the deep sedative effects, DEX is associated with minor respiratory depression, even when it is dosed in plasma levels up to 15 times with those usually obtained during administration, offering a higher level of safety, compared with other sedative agents ([@B182]; [@B50]). Hypercapnic stimulation is preserved and limits apnea or attenuates the stimulatory effect of CO2 levels. In volunteers, DEX infusions preserved the hypercapnic ventilatory response, the respiratory rate was significantly increased, and the overall apnea/hypopnea index was significantly decreased. The distribution of inspiratory time/ventilatory cycle time showed an increased peak. More importantly, DEX exhibited a hypercapnic arousal phenomenon similar to that which has been described during natural sleep ([@B71]). Compared with opioid infusions, DEX can be infused by a tracheal tube in a safe manner ([@B134]).

DEX Molecular Pathways {#s3_3}
----------------------

DEX modulates some intracellular pathways such as G protein-coupled receptors, protein kinase C (PKC) activity, and inositol triphosphate (IP3) levels in renal cells. Protein kinase C is relevant as an ischemic preconditioning trigger providing organ protection, the opening mitochondrial ATP-sensitive K+ channels, and the induction of protective gene transcription ([@B32]). DEX determines the *in vitro* activation of the adenylyl cyclase-cyclic adenosine monophosphate (cAMP), suggesting that DEX may have a protective effect through the modulation of PKC activation-induced HSP27 phosphorylation ([@B176]; [@B177]). The α2-AR-focal adhesion kinase-Src-phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) ([@B57]; [@B135]), and the mitochondrial ATP-sensitive K+ channel pathways are involved in the preconditioning and postconditioning mechanisms induced by DEX against hippocampal oxidative damage ([@B34]; [@B35]). Treatment with DEX reduces central nervous injury in rats subjected to focal I/R, which is mediated by the activation of the PI3K/Akt and ERK1/2 pathways ([@B204]). Moreover, DEX attenuates hippocampal CA1 long-term potentiation. α2-ARs and imidazoline I2 receptors are modulated by DEX ([@B174]). Regarding the neuroprotective effects, epidermal growth factor receptor activation in astrocytes *in vivo* represents an important process secondary to α2-AR activation ([@B42]). Moreover, the α2-ARs also activate the mitogen-activated protein kinase pathway and thus determine the proliferation of tubular cells derived from the human intestinal epithelium in rats. ([@B154]; [@B33]; [@B89]).

Previous animal experiments have shown benefits and cardioprotective effects of DEX administration in the ischemic heart ([@B151]; [@B192]; [@B130]). Furthermore, it has been shown that DEX administration causes activation of signaling pathways associated with cardiac survival. The DEX pretreatment of rat hearts induces Erk 1/2, Akt and eNOS activation, improves myocardial function and reduces myocardial infarction size after regional ischemia-reperfusion (I/R) of the heart in the *in vivo* and *ex vivo* models ([@B75]). In this study, the three isotypes of α2-adrenergic receptors were detected in the whole cardiac tissue and the α2A and α2C adrenergic receptors were detected only in isolated cardiomyocytes. The authors concluded that independently from autonomic nervous system modulation, DEX cardioprotective effects are mediated by activation of pro-survival PI3K/Akt signaling pathway after cardiac α2-adrenergic receptor stimulation. More recent studies have demonstrated the role of endothelial α2-adrenergic receptors with beneficial effects on DEX against I/R injury ([@B148]; [@B38]), activating the eNOS/NO cardioprotective signaling pathways ([@B97]).

Molecular Mechanisms of Dexmedetomidine Effects on Heart and Lung {#s3_4}
-----------------------------------------------------------------

The mitochondria are critical coordinators of cellular life through their function on bioenergetics, producing energy, and their role in apoptosis, regulating cell death ([@B184]). The mitochondria supply 90% of the cardiomyocyte ATP, which is necessary to support contraction, metabolism, and ion homeostasis, and thus have a critical role in cardiac function ([@B65]; [@B139]). Mitochondrial dysfunction has been involved in the pathophysiology of cardiovascular disease, including ischemia/reperfusion (I/R) injury, arrhythmogenesis, and left ventricular dysfunction ([@B105]; [@B21]; [@B22]). It has been shown that DEX preconditioning rat cardiomyocytes through mitochondrial protection diminishes reactive oxygen species (ROS)-induced apoptosis ([@B113]; [@B188]). Dexmedetomidine prevented the increase in the oxygen consumption rate and ROS levels induced by H2O2. It improved the coupling efficiency of the mitochondria potentially by preserving mitochondrial membrane potential (MMP) in the presence of mitochondrial uncouplers ([@B113]; [@B188]). Moreover, dexmedetomidine decreased the H2O2-induced activity of caspase 12, and the mRNA levels of Grp78 (glucose regulated protein 78 kDa) and IRE1α (serine/threonine protein kinase/endoribonuclease), three signaling pathways that determine ER stress mediated cell death ([@B113]). The cardioprotective effect of DEX has also been evidenced in isolated rat hearts, in which DEX preconditioning (10 nmol/l before ischemia for 15 min) had protective effects against I/R injury. The agonist attenuates myocardial cell death and improves cardiac function through mechanisms that involve the inhibition of the mitochondrial permeability transition pore (mPTP) opening at reperfusion time ([@B83]). The opening of the mPTP results in respiratory chain uncoupling, mitochondrial ATP synthesis reduction, mitochondrial swelling and cell death ([@B74]; [@B61]). Thus, the mPTP is a selective pharmacological target for cell death prevention in pathophysiological conditions. Cyclophilin D, a regulator of the mPTP, protects against cell death in response to different injuries ([@B120]; [@B117]; [@B143]). The protection of the mitochondrial function, by inhibiting the mPTP opening and thus preserving the MMP, is a plausible mechanism by which DEX exerts its cardioprotective effects.

As an anesthesia co-adjuvant, dexmedetomidine can improve hemodynamic stability and reduce the doses of anesthetics and analgesics during surgery, and it may contribute to the prevention of postoperative cognitive dysfunction (POCD) ([@B19]). In patients undergoing elective surgery under general anesthesia induced by remifentanil (0.5--1 µg/kg/h) and propofol (3--10 mg/kg/h), the addition of dexmedetomidine (0.2 µg/kg/h) during induction and maintenance periods improved POCD, through the mechanism involving mitochondrial function protection. Dexmedetomidine attenuated the decrease in postoperative National Institutes of Health Stroke Scale (NIHSS) and Auditory Verbal Learning Test (AVLT) scores and the increase in the Beck Depression Inventory (BDI) score. In terms of mitochondrial function, dexmedetomidine alleviated the postoperative decrease in mitochondrial membrane potentials and the activities of the mitochondrial respiratory complexes I--IV in leukocyte cells ([@B21]; [@B22]). Moreover, dexmedetomidine has been shown to have neuroprotective effects against apoptosis through mechanisms involving mitochondrial functions ([@B52]). Apoptosis is a major pathway in I/R‐induced neuronal and cardiac insults ([@B17]). Dexmedetomidine prevented apoptosis induced by I/R by protecting against MMP reduction, Bax and cytochrome c release as well as caspase activation in neuro-2a and NB41A3 neuronal cells ([@B193]). Dexmedetomidine also protected PC12 cells from lidocaine-induced apoptosis, diminished the mRNA levels of COL3A1, increasing Bcl2, and inhibiting caspase 3 activation ([@B186]). Interestingly, this effect was reversed by the miR-let-7b inhibitor, indicating that dexmedetomidine exerts neuroprotection *via* miR-let-7b, a recognized modulator of mitochondrial function ([@B8]; [@B186]). Dexmedetomidine protected PC12 cells against glutamate-induced cytotoxicity through its mitochondrial protective effect, stabilizing MMP and Ca2+ homeostasis, and through its antioxidant properties, reducing malondialdehyde and augmenting superoxide dismutase activity ([@B202]).

In addition, DEX has demonstrated neuroprotective effects against ischemia or tissular hypoxia. In an *in vivo* neuroprotection model, DEX prevented the brain damage induced by cerebral ischemia-reperfusion in rats by activating mitochondrial ATP-sensitive potassium channel (mitoKATP) ([@B199]). Dexmedetomidine (50 μg/kg injected intraperitoneally before ischemia and after onset of reperfusion) prevented the I/R-induced increase in the neurological deficit score, pro-oxidant enzyme activity (such as myeloperoxidase and malondialdehyde) in the brain and pro-inflammatory cytokine levels in plasma (like IL-6 and TNF-α) ([@B199]). The neuroprotective mechanism by DEX was not observed in the presence of 5-hydroxydecanoate, a mito-KATP channel blocker, which suggests that its pharmacological target involves mitochondrial components ([@B199]).

Acute lung injury (ALI) is a common condition in critical patients, and lipopolysaccharide (LPS) is the most important pathogen that determines the development of ALI in sepsis ([@B59]). Dexmedetomidine has been reported to attenuate LPS-induced ALI in rats ([@B62]; [@B54]). Specifically, DEX (50 µg/l 30 min prior to LPS cell treatment) diminished LPS-induced mitochondrial dysfunction by preventing the reduction in cellular ATP levels and MMP in rat type I alveolar epithelial cells (AECs) ([@B54]). In addition, the same concentration of DEX markedly reduced the LPS-induced mitochondrial-dependent apoptotic pathway in AECs, as the 2α-adrenoreceptor agonist decreased the cytosolic cytochrome c and caspase 3 activity ([@B113]). *In vivo* dexmedetomidine (50 ug/kg, 30 min prior LPS administration) also decreased LPS-induced apoptosis, as demonstrated by attenuating DNA fragmentation, activation of caspase 3, Bax upregulation and Bcl-2 downregulation in lungs. Furthermore, DEX markedly diminished LPS-induced oxidative stress, as evidenced by the downregulation of cellular ROS in AECs and lipidperoxidation levels in serum ([@B54]). Moreover, dexmedetomidine treatment inhibited hyperoxia or the LPS/ATP-induced decrease of MMP and mitochondrial ROS production in RAW264.7 cells; therefore, through this mechanism, dexmedetomidine restrained the NLRP3 inflammasome activation-mediated increased release of IL-1β, IL-18, and TNF-α ([@B203]). Dexmedetomidine may contribute to reducing ALI, by preventing the activation of macrophages through a mechanism that involves mitochondrial protections or by inducing neutrophil cell death, also by targeting the mitochondria ([@B98]). Dexmedetomidine (100 ng/ml, 24 h incubation) has been shown to induce apoptosis in neutrophils through mechanisms involving caspase cascade activation and mitochondrial intrinsic pathway triggered by decreasing the MMP ([@B98]). In the intrinsic pathway, loss of MMP induces the mitochondrial disruption, and mitochondrial pro-apoptotic proteins are released into the cytosol, triggering the activation of caspase-9 ([@B184]). Interestingly, DEX-induced apoptosis is unlikely to be 2α-adrenoreceptor-mediated, as yohimbine, a 2α-adrenoreceptor antagonist, did not attenuate its pro-apoptotic effects ([@B98]). As the pro-apoptotic effect of dexmedetomidine is evidenced at a concentration 100-times greater than is considered clinically relevant (1 ng/ml), the clinical administration is safe for ICU patients.

The molecular signaling pathways trigger by DEX, and pathophysiological effects are shown in [**Figure 1**](#f1){ref-type="fig"}.
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Clinical Efficacy for the Use of DEX in Different Clinical Settings {#s4}
===================================================================

Diverse effects of DEX include sedation, analgesia, anxiolysis, sympatholysis, cardiovascular stabilization and reduction of anesthetic requirements with preservation of respiratory function ([@B15]; [@B92]; [@B116]). Although labeled for short-term sedation only (24 h or less), its use has been demonstrated to be safe for long-term sedation in critically ill patients ([@B133]), in whom pharmacokinetics is often unpredictable ([@B187]). Other important benefits are its easy dosage titration (reducing oversedation risk), its several routes of administration, and minimal clinical impact of its metabolites ([@B41]; [@B55]). These features have given DEX an advantage over other sedatives, such as opioids and benzodiazepines. Its clinical use has been focused on two major scenarios: periprocedural sedation in anesthesia and "light to mild" sedation in the ICU ([@B6]).

DEX as Peri-Procedural Sedation in Anesthesia {#s4_1}
---------------------------------------------

The unique properties of DEX make it suitable for sedation and analgesia during the entire perioperative state in a wide range of procedures ([**Table 1**](#T1){ref-type="table"}). DEX can be used as premedication, as an anesthetic adjunct for anesthesia or as a postoperative sedative process. This versatility is further enhanced by the property of being compatible with practically all administration routes used in usual perioperative care ([**Table 2**](#T2){ref-type="table"}). This is particularly useful in pediatrics, non-collaborative patients, or those with insufficient venous access ([@B160]; [@B187]; [@B167]).

###### 

Reported use of DEX in several settings of perioperative care.

  ----------------------------------------------------------- -----------------
  Epidural anesthesia                                         [@B158]
  Spinal anesthesia                                           [@B87]
  Caudal anesthesia                                           [@B47]
  Peripheral nerve block                                      [@B36]
  Intraarticular use (Arthroscopic surgery)                   [@B3]
  Intensive care unit sedation                                [@B147]
  Transesophageal echocardiography                            [@B28]
  Colonoscopy                                                 [@B82]
  Awake carotid endarterectomy                                [@B9]
  Awake intubation                                            [@B14]
  Vitreoretinal surgery                                       [@B56]
  Tonsillectomy/Adenoidectomy                                 [@B131]/[@B107]
  Shockwave lithotripsy                                       [@B94]
  Attenuated response to tracheal intubation and extubation   [@B60]
  Post-operative analgesia                                    [@B181]
  Cardiac surgery                                             [@B190]
  Neurosurgery                                                [@B10]/[@B11]
  Sedation in obese patients                                  [@B69]
  Use in MRI                                                  [@B119]
  Endoscopic retrograde cholangio-pancreatography             [@B115]
  Ureteroscopy                                                [@B161]
  ----------------------------------------------------------- -----------------

###### 

Dosage of DEX used in several administration routes.

  -----------------------------------------------------------------------------------
  Route                    Dosage                                           
  ------------------------ ------------------------------------------------ ---------
  Intravenous              For ICU sedation 0.2--1.4 mcg/kg/h, may start\   [@B147]
                           1.0 mcg/kg bolus\                                
                           For Procedural sedation 0.2--1 mcg/kh/h          

  Intranasal               1--2 mcg/kg                                      [@B26]

  Buccal                   1--2 mcg/kg                                      [@B26]

  Intramuscular            2.5 mcg/kg                                       [@B172]

  Spinal                   0.1--0.2 mcg/kg                                  [@B87]

  Epidural                 1--2 mcg/kg                                      [@B158]

  Peripheral nerve block   1 mcg/kg                                         [@B127]
  -----------------------------------------------------------------------------------

Several meta-analyses have evaluated the use of DEX in the perioperative period. [@B138] focused on cardiovascular stress response to surgical injury. They found patients receiving DEX had significantly lower blood pressure and heart rate. Conversely, they also found more hypotension and bradycardia. In an earlier publication, [@B171] found that DEX reduced the amount of intravenous and inhaled anesthetics, but did not reduce muscle relaxant dosages. Other authors have shown a reduction in postoperative delirium (see below), pain ([@B156]; [@B157]; [@B73]) and shivering ([@B106]; [@B111]; [@B70]). The effect of DEX on postoperative shivering is still not well understood ([@B114]). Although some positive results have been shown in clinical trials, the evidence is still regarded as poor. Moreover, DEX is not superior to other anti-shivering agents, such as fentanyl, meperidine, tramadol or clonidine.

DEX in the ICU {#s4_2}
--------------

Sedatives are administered to critically ill patients to alleviate discomfort, prevent agitation-related harm, decrease metabolic demand (reducing O~2~ consumption and CO~2~ production), and improve tolerance and adaptation to mechanical ventilation ([@B173]; [@B25]). In order to reduce the adverse events associated with sedative drugs, clinical guidelines have been issued ([@B7]; [@B40]). One of the principal indication for the use of DEX is to alleviate the pain and induce sedation in critical patients by targeting light levels of sedation. However, its administration is not recommended in acute respiratory distress syndrome (ARDS), shock or intracranial hypertension. These recommendations match in many aspects, the pharmacological and clinical properties of DEX, explaining its increasing use in intensive care units ([@B37]).

Among the main reported benefits associated with DEX use in the ICU are shorter ICU stays and mechanical ventilation duration ([@B25]), less use of benzodiazepines, and lower incidence of delirium ([@B170]; [@B126]). Conversely, bradycardia and hypotension occurrence have been described in ICU patients with a minimal impact on mortality ([@B7]; [@B27]; [@B40]).

DEX in Invasive Mechanical Ventilation {#s4_3}
--------------------------------------

As noted earlier, one of the main indications of sedoanalgesia in the ICU is to improve tolerance and adaptation to mechanical ventilation, as the prevalence of anxiety and agitation in ventilated patients of up to 80% has been reported ([@B179]; [@B25]). Conversely, in the case the use of oversedation in ICU patients the deleterious effects are evidenced. In this case, the clinical effects include: increase in the occurrence of delirium, immobility, respiratory muscle atrophy, long-term mechanical ventilation duration, prolonged of ICU stays, and increased costs and even a rise in mortality ([@B149]; [@B194]; [@B100]; [@B144]). Thus, the optimal management of sedation in this scenario has been the subject of extensive debate. For a better understanding of this issue, it is essential to distinguish between two different scenarios where mechanical ventilation is frequently used. The first involves an unstable patient, where deep sedation is required, often associated with a neuromuscular blockade, and where protective ventilation is sought. This patient needs complete suppression of spontaneous respiratory effort, with the physiological objective of reducing the associated pulmonary injury ([@B197]), decreasing metabolic demand ([@B102]) or reducing intracerebral pressure ([@B128]). Examples of this situation include ARDS, severe shock, or unstable intracranial hypertension. In these settings, the use of DEX does not seem to have a role.

In the second scenario, the patient has a less severe condition than the one previously described. Clinical stability has been reached, the cause that led to ICU admission is in clear resolution, resuscitation has been completed, or the effort for strict "pulmonary protection" has ceased. In other words, the patient has entered the "dereanimation" phase ([@B163]), where the target is the reduction of the morbidity attributed to the interventions carried out in the ICU. In this scenario, it is highly likely that a more superficial sedation, which favors controlled spontaneous ventilatory effort, mobility, and awakening, will produce better clinical outcomes. DEX has a role in this setting and has indeed shown optimal outcomes in clinical trials ([@B53]; [@B66]).

In summary, in patients undergoing mechanical ventilation in the ICU who do not require deep sedation, the use of DEX is associated with fewer days in the ICU, shorter time to extubation and a decrease in the incidence of delirium, although no differences in mortality have been shown ([@B144]; [@B170]; [@B126]).

DEX in Non-Invasive Ventilation {#s4_4}
-------------------------------

Non-invasive ventilation (NIV) has shown to be beneficial in the treatment of acute respiratory failure associated with acute cardiogenic pulmonary edema, chronic obstructive pulmonary disease and postoperative care, amongst others ([@B81]; [@B132]; [@B12]). These benefits are mainly explained by decreasing the need for intubation and connection to mechanical ventilation ([@B132]; [@B12]). One of the leading causes of NIV failure is agitation, non-tolerance, and non-cooperative patient, reaching rates of up to 22% ([@B18]). In these situations, light sedation has been proposed, and some series have reported its use in up to 20% of patients ([@B67]). DEX has been used in this setting considering its sedative and analgesic effect, without depressing the respiratory center or interfering with airway protection, in addition to its excellent safety profile ([@B67]). Current evidence suggests that it is a safe choice, especially in centers where there is a specialized NIV team ([@B67]). Regarding its effectiveness, the literature is scarce and otherwise contradictory.

DEX and Delirium {#s4_5}
----------------

Delirium is a common problem in clinical medicine, which is defined as an acute alteration of attention and awareness, attributable to a general medical state ([@B4]). In a comprehensive review ([@B80]), the highest incidence rates were observed in ICU and postoperative care settings, ranging between 19 and 82%. Although usually transient, it is associated with worse clinical outcomes, including longer hospital length of stay, increased costs, more days on mechanical ventilation, and long-term cognitive impairment and dependence ([@B142]). Moreover, patients who develop delirium in the ICU experience a threefold increase in six-month mortality risk compared to matched, non-delirious ICU patients ([@B48]). Among the modifiable risk factors, the use of sedatives and opioid agents has been identified as one of the most relevant, conferring a relative risk of 4.5 in validated predictive models ([@B80]). Hence, it is not surprising other drugs have been tested to provide analgesia or light sedation with a lower delirium risk. Several systematic reviews and meta-analyses have evaluated DEX versus opioids, benzodiazepines, and propofol in terms of delirium occurrence ([@B121]; [@B136]; [@B43]; [@B51]). The most recent one by [@B51] included 25 trials regarding delirium prevention and three regarding its treatment. The authors found that the use of DEX was associated with significantly minor incidence of delirium when compared to the placebo group, standard sedatives, or opioids. In terms of treatment, the small sample and different comparators made it impossible to argue in favor of or against its use. Recently, prophylactic nightly use of DEX has shown to reduce delirium ([@B164]). The results of this industry-funded, two-center, double-blind, placebo-controlled trial have not been replicated but remain promising.

Current published clinical guidelines ([@B40]) do not directly support the use of DEX for delirium prevention. Still, they do acknowledge the use of DEX, as a sedoanalgesia, is associated with a lower incidence of delirium compared to strategies based on benzodiazepines or opioids. No recommendations are made concerning its prophylactic nightly use. Finally, regarding delirium treatment, guidelines suggest the use of DEX in patients undergoing mechanical ventilation, in which agitation precludes weaning/extubation.

DEX in Neurological Injury {#s4_6}
--------------------------

Scare evidence exists for the neuroprotective effects of DEX in children following neurological injury ([@B2]). In addition, there are no trials showing the long-term effects of DEX on memory acquisition in children; this is probably due to the inherent challenges associated with designing trials in children. As a result, clinical evidence for the neuroprotective effects of dexmedetomidine in children is limited to cases of delirium following anesthetic infusion, and sedation in critical care patients ([@B167]).

Intracranial lesions or trauma-related damage activate immune inflammation and neuroendocrine responses, causing ischemic brain injury. Studies have shown that inflammatory pathways mediated by neuroendocrine hormones and proinflammatory cytokines is implicated in the pathophysiology of ischemic brain injury. Alpha2-adrenoceptor agonist, dexmedetomidine, is used as neuroprotectant in anesthetic procedures ([@B84]). However, meta-analyses to evaluate the neuroprotection of dexmedetomidine against ischemic brain injury are still lacking.

DEX exerts protective effects on brain injury through multiple mechanisms, such as decreasing local inflammation and improving the cerebral oxygen metabolism ([@B129]). These mechanisms underlay the effect of DEX in reducing the ischemic zona and infarct size in an animal model of brain hypoxia-ischemia injury ([@B146]). Experimental approaches indicated that DEX decreases tumor necrosis factor (TNF)-α, interleukin (IL)-6 levels; and maintains a high level of superoxide dismutase (SOD) activity ([@B185]). In addition, DEX achieves hemodynamic stability and attenuates the stress-related increase of intracranial pressure ([@B159]). In this case, the modulation of inflammatory and stress hormones levels are all relevant predictors of clinical outcome following ischemic brain injury ([@B153]).

DEX and Sepsis {#s4_7}
--------------

Other effects of DEX have been shown *in vitro,* such as anti-inflammatory mechanism in sepsis. These effects are mediated by its action on adrenergic receptors that trigger NF-kB inhibition and level reduction of TNF-α, IL-6, IL-8, and HMGB1 ([@B93]). Moreover, *in vivo* sepsis, the vagus nerve and α7nAChR-mediated cholinergic anti-inflammatory pathway are required for the anti-inflammatory effect of DEX ([@B195]).

Patients that develop sepsis may have marked respiratory and cardiovascular depression. Early stages of sepsis are associated with a drop in the systemic vascular resistance, high cardiac output, and a hypercontractile state ([@B200]). The improvement of the sepsis management often requires that patients receive anesthesia as well as analgesia. This is due to the unstable cardiovascular state, changes that exacerbate the cardiac dysfunction. Anesthetic drugs in this setting, should not inhibit compensatory hemodynamic responses. Unfortunately, current intravenous drugs and inhalational pharmacological agents do not meet these considerations ([@B200]; [@B20]). However, DEX seems promising in this context, and mechanistic, pharmacodynamic, and pharmacokinetic studies with DEX in critical septic patients have increased in recent years. Recent evidence in septic shock sedated patients have shown that for a comparable level of sedation, switching from propofol to dexmedetomidine resulted in a reduction of norepinephrine requirements in septic shock patients ([@B122]).

[**Table 3**](#T3){ref-type="table"} shows the benefits of adding DEX in different clinical settings.

###### 

Benefits of adding DEX in different clinical settings.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical scenario                 Benefits of using DEX                                                                             References
  --------------------------------- ------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peri-procedural sedation          Effective sedation in diverse procedural scenarios.\                                              [@B45]; [@B96]; [@B15]; [@B44]; [@B183]; [@B5]; [@B137]; [@B171]; [@B140]; [@B168]; [@B109]; [@B78]; [@B156]; [@B157]; [@B138]; [@B30]; [@B64]; [@B106]; [@B111]; [@B116]; [@B198]; [@B201]; [@B70]; [@B160]; [@B170]; [@B189]; [@B112]; [@B167]; [@B187]
                                    Diverse administration routes.\                                                                   
                                    Reduces sympathetic\                                                                              
                                    and stress response to surgery.\                                                                  
                                    Sparing effects of anesthetic agents\                                                             
                                    Reduces postoperative delirium, shivering and pain                                                

  ICU                               Reduces ICU stays and duration of mechanical ventilation\                                         [@B15]; [@B170]; [@B25]; [@B126]; [@B51]
                                    Sparing effects of benzodiazepines\                                                               
                                    Delirium prevention                                                                               

  Invasive Mechanical Ventilation   Shorter Time to extubation and ICU stay. Decrease incidence of delirium                           [@B53]; [@B144]; Su et al., 2016; [@B66]; [@B126]

  Non-invasive Ventilation          Sedation and analgesia without respiratory depression                                             [@B67]

  Delirium                          Reduces incidence of delirium in ICU and postoperative period                                     [@B121]; [@B136]; [@B116]; [@B43]; [@B51]; [@B164]

  Neurological Injury               Potential neuroprotection in young children. Potential neuroprotection in Ischemic brain injury   [@B146]; [@B2]; [@B167]; [@B159]

  Sepsis                            Anti-inflamatory effects in sepsis. Potential hemodynamic stability                               [@B195]; [@B122]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Concluding Remarks {#s5}
==================

Dexmedetomidine is a highly selective alpha-2 receptor agonist. Since its approval by the FDA for sedation in the ICU, its applications have expanded significantly because of its unique mechanism of action, minimal effect on the respiratory drive, and ideal safety profile. Its applications include premedication for pediatric and adult patient populations, procedural sedation and monitored anesthesia care, adjuvant for general and regional anesthesia, perioperative pain control, and postoperative delirium. Clinical evidence show that dexmedetomidine has little effect on the respiratory drive; it still can cause airway obstruction in combination with other anesthetic agents ([@B125]).

Preclinical studies with DEX on murine models have revealed protective effects, including the inhibition of proinflammatory cytokine production ([@B178]). In *vitro* studies with human whole blood samples have shown that DEX significantly suppresses Lipopolysaccharide induced proinflammatory mediators dose-dependently ([@B93]). Clinical investigations with human subjects evaluating the effects of DEX on serum inflammatory cytokines during perioperative conditions show inconsistencies in the outcomes ([@B110]; [@B108])

Multiple trials and meta-analyses also suggest that DEX use is associated with less delirium and cognitive disturbance, faster weaning from mechanical ventilation, and decreased time to extubation compared with other sedative agents ([@B162]; [@B196]). As such, DEX seems to be an ideal primary anesthetic agent in the sedation of intubated and mechanically ventilated critical patients.

Regarding their molecular effects, DEX pre-, intra- and postconditioning treatments showed neuroprotective and cardioprotective effects reduced cell necrosis, although only preconditioning showed antiapoptotic mechanisms ([@B146]; [@B38]). Dexmedetomidine treatments also reduced IL-6 and TNF-α levels, especially in the preconditioning groups. Oxidative stress is attenuated with all DEX-preconditioning treatments, but only with the higher dose in the intraconditioning group, and no effects were observed in the postconditioning ([@B150]; [@B23]). According to these changes, conditioning strategies increased BDNF levels and attenuate mitochondrial dysfunction *in vivo* and *in vitro* models of IR injury ([@B72]).

Cardiac preconditioning effects associated with DEX administration validated in animal models are shown in [**Figure 2**](#f2){ref-type="fig"}.

![Cardiac preconditioning effects associated with DEX administration validated in animal models. These strategies that determine an attenuation of oxidative stress and inflammation in cardiac tissue are very important to improve the clinical outcome of patients subjected to ischemia-reperfusion (IR) injury. ROS, reactive oxygen species; MMP Matrix metalloproteinases; eNOS, endothelial nitric oxide synthase; NO, nitric oxide.](fphar-10-01641-g002){#f2}

Overall, evidence shows that DEX may attenuate the mortality and inhibit inflammatory processes, as it enhances the activity of the immune system while reducing its systemic reaction and lowering cytokine levels. Moreover, DEX succeeds in alleviating heart injury during sepsis, acting beneficially for microcirculation, and shows a neuroprotective role by inhibiting cell death pathways. Various molecular signaling pathways, such as mitochondria or the modulation of transcriptional factors, are under study in both *in vivo* and *in vitro* models.

Therefore, we can say with the reviewed evidence that DEX can be used as a drug for the study of translational models from the cellular and animal point of view and in clinical trials with humans which including cardiovascular and ventilator outcomes. The biological activities associated with DEX continues keep growing, and its diverse effects suggest that it may offer a novel therapeutic approach for the treatment of human diseases with I/R involvement.
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